StockNews.AI
ALGS
StockNews.AI
162 days

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results

1. Aligos progresses towards Phase 2 clinical study for ALG-000184 in mid-2025. 2. Company completed $105 million funding backed by supportive institutional investors. 3. ALG-000184 shows promising results, achieving 100% sustained HBV DNA suppression. 4. R&D expenses decrease, but net loss increases significantly year-over-year. 5. Three clinical trials for ALG-097558 commenced in 2024, funding from external sources expected.

Earnings
-19.63%Current Return
VS
-3.22%S&P 500
$12.9403/10 08:05 AM EDTEvent Start
$10.403/11 02:12 PM EDTLatest Updated
16m saved
Insight
Article

FAQ

Why Bullish?

Positive clinical data for ALG-000184 and secured funding likely to boost investor sentiment.

How important is it?

Key advancements in drug pipeline and funding positively influence stock performance outlook.

Why Short Term?

Immediate increase in investor confidence due to upcoming Phase 2 study in mid-2025.

Related Companies

GILDABBVBMY
March 10, 2025 08:00 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2024. “2024 was a pivotal year for the company, paving the way for the future of Aligos,” stated Lawrence Blatt, Ph.D., MBA, Chairman, President, and Chief Executive Officer of Aligos Therapeutics. “That future looks bright as we move ALG-000184 closer towards a Phase 2 clinical study, which is expected to begin in mid-2025. We continue to believe our CAM-E has the potential to be a first- and best-in-class candidate, by acting as a disease modifying agent for patients in need of better outcomes. Our recent fundraising is backed by investors supportive of our vision for ALG-000184, which has the potential to replace standard of care and become the backbone of treatment for next-generation therapies for chronic hepatitis B virus infection.” Recent Business Progress Corporate Updates Lesley Ann Calhoun was promoted to Executive Vice President, Chief Operating Officer and Chief Financial OfficerThe Company completed a $105 million private placement financing on February 13, 2025, which included participation from both new and existing institutional investors Pipeline Updates ALG-000184: Potential first-/best-in-class small molecule CAM-E for chronic hepatitis B virus infection Dosing continues in the ongoing Phase 1 study, with subjects expected to dose for up to 96 weeks. 96-week data readouts are planned to be presented this year at upcoming scientific conferencesInterim data from up to 92 weeks following an oral daily dose of 300 mg ALG-000184 in both HBeAg+ and HBeAg- subjects with chronic hepatitis B virus infection were presented at the American Association for the Study of Liver Disease’s (AASLD) The Liver Meeting (TLM) 2024 Data from ≤84 weeks following an oral daily dose of 300 mg ALG-000184 monotherapy demonstrated sustained HBV DNA suppression (

Related News